The company highlighted three primary growth drivers: plozasiran, obesity programs, and the emerging CNS pipeline. Plozasiran ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals ...